普拉米佩克索尔过度激活了外部球体,并在帕金森病的小鼠模型中损害了决策能力
Hisayoshi Kubota1, Xinzhu Zhou1, Xinjian Zhang1
1Division of Behavioral Neuropharmacology, International Center for Brain Science (ICBS), Fujita Health University, Toyoake 470-1192, Aichi, Japan.
International journal of molecular sciences
|August 29, 2024
概括
对帕金森病 (PD) 的多巴胺治疗可以影响决策. 在PD小鼠中,pramipexole (PPX) 通过过度激活外部球神经元,增加了风险选择,这表明了新的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 行为科学 行为科学
背景情况:
- 帕金森病 (PD) 的多巴胺替代疗法可以导致决策障碍,例如病态博.
- 这些不良影响的潜在神经生物学机制尚未完全理解.
研究的目的:
- 调查多巴胺D3受体 (D3R) 偏好性激动剂pramipexole (PPX) 对PD小鼠模型决策的影响.
- 为了确定参与PPX诱导的决策缺陷的神经生物学途径.
主要方法:
- 用6氧多巴胺神经毒素生成了帕金森病模型小鼠.
- 小鼠接受了PPX治疗,并使用爱荷华州博任务进行评估.
- 使用了D3R对抗性,c-Fos表达分析,以及对外部白色球体 (GPe) 的化学遗传抑制.
主要成果:
- 在PD模型小鼠中,PPX治疗增加了不利,高风险/高回报的选择.
- 这种效应被选择性D3R抗剂 (PG-01037) 逆转.
- PPX诱导了GPe神经元的过度激活,与间接途径相关,通过GPe抑制正常化,挽救决策.
结论:
- 在间接途径中GPe神经元的过度激活会损害PD模型小鼠的决策能力.
- 这项研究确定了PD中多巴胺激动剂治疗期间病态博的潜在机制.
- 针对GPe过活化可能为PD相关决策缺陷提供治疗策略.
相关概念视频
01:24Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
01:15Parkinson's Disease: Overview
499
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
499